XORTX Hikes on Revealing Drug Supply

XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that manufacturing and packaging of clinical drug supply for the XRX-OXY-102 clinical trial has been completed.
Production of XORTX’s clinical drug supply is based on proprietary synthetic pathway for production of high yield pure oxypurinol, then formulated using our proprietary and patented formulation of this drug.
This process to produce the formulation and tablet format the Company aims to advance through marketing approval is a key step forward for the XRx-026 program for the treatment of gout.
The XRx-026 program is our lead program focused on the treatment of individuals with symptoms of gout. In parallel with the manufacturing processes, method development and validation of tablet, drug development team activities include the preparation of the Clinical Trial Application for filing with Health Canada. Validation data from this manufacturing process will be included in the CTA.
The application describes the Company’s clinical development plan for XRx-026 and its intention to advance the program toward regulatory approval in Canada in parallel with its planned Investigational New Drug application filing with the US Food and Drug Administration.
XRTX shares spiked 19 cents, or 17.8%, to $1.30.

Related Stories